Will Insurance Cover Mounjaro for Weight Loss in 2026?

Mounjaro and Zepbound both contain tirzepatide, a GIP/GLP-1 dual receptor agonist made by Eli Lilly. The FDA approved Mounjaro in May 2022 (NDA 215866) for type 2 diabetes mellitus. Zepbound received FDA approval in November 2023 for chronic weight management in adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related condition. That approval distinction, not the underlying chemistry, drives every insurance coverage decision for patients seeking Mounjaro for weight loss in 2026. When a prescriber writes Mounjaro for a patient without type 2 diabetes, most commercial plans, Medicare, and Medicaid treat the use as off-label for an indication they do not cover.

Eli Lilly uses a flat-rate wholesale acquisition cost (WAC) of $1,079.77 per month for all six Mounjaro dose strengths (2.5 mg through 15 mg KwikPen). Cash prices at retail pharmacies in May 2026 range from approximately $1,040 at Costco to $1,190 at CVS and Walgreens. GoodRx coupons reduce these cash prices by $30 to $110, but the net result is still roughly $990 to $1,050 at most chains. Patients prescribed Mounjaro for weight loss who do not have commercial insurance covering it and are not eligible for the patient assistance program face this full cash cost. Patients with Medicare Part D who want covered GLP-1 therapy for weight loss should check whether Zepbound qualifies through the new GLP-1 Bridge rather than seeking coverage of Mounjaro specifically.

A critical policy change arrived in 2026: CMS launched the Medicare GLP-1 Bridge program effective July 1, 2026, giving Medicare Part D enrollees access to weight-loss-labeled GLP-1 drugs at a $50 monthly copay. The covered drugs under the Bridge are Wegovy (all formulations), Zepbound (KwikPen), and Foundayo. Mounjaro is explicitly excluded from the Bridge because it carries only a diabetes FDA label. This exclusion matters for patients prescribed Mounjaro off-label for weight loss: Medicare will not pay for it under the Bridge, and Medicare Part D plans do not cover it for weight loss under the 2003 Medicare Modernization Act anti-obesity exclusion. The Inflation Reduction Act selected tirzepatide (Mounjaro and Zepbound) for a future round of Medicare drug price negotiation under the Inflation Reduction Act, with negotiated prices potentially effective 2027 or later. For Medicaid, approximately 13 states cover GLP-1 drugs for obesity in their fee-for-service programs as of 2026; check your specific state formulary or visit Medicaid income limits for state-specific coverage context.

What Mounjaro Weight Loss Coverage Costs by Point of Pay (2026)

The price you pay depends almost entirely on WHERE you pay. The same mounjaro weight loss coverage can cost many times more at a hospital than at your local pharmacy:

Why Hospitals Charge So Much

Mounjaro is a self-administered subcutaneous injection taken once per week via KwikPen. Patients manage this at home, so Mounjaro rarely appears on inpatient hospital bills as an administered treatment. When it does appear on a hospital bill, the charge typically reflects continuation of the patient's outpatient regimen during a hospital admission for an unrelated condition. In that scenario, the hospital marks up its acquisition cost (typically $700 to $900 per pen internally) by a facility fee multiplier that can push the line item to $1,200 to $2,500 per month on an itemized bill. Reviewing that line item against the Eli Lilly WAC of $1,079.77 and requesting a charge correction is the most common recourse.

Mounjaro does not have a dedicated HCPCS Level II J-code for 2026 routine outpatient billing. In facility settings, providers use J3490 (unclassified drugs) or J3590 (unclassified biologic) when billing tirzepatide. This lack of a specific code makes it harder for patients to cross-check a hospital charge against a public benchmark. When you see a J3490 charge for tirzepatide on an itemized bill, request that the billing department provide the exact number of units dispensed and the NDC code. Compare the billed amount to the Eli Lilly published WAC. Charges more than 30 percent above WAC warrant a formal billing dispute through the hospital's patient financial services office.

The bigger affordability problem for patients taking Mounjaro for weight loss in 2026 is not the hospital markup but the insurance denial. Most of the financial pain comes from prior authorization walls, step-therapy requirements, or outright plan exclusions of anti-obesity drugs. Patients who have been denied coverage for Mounjaro for weight loss should focus on the appeal process, the Zepbound alternative for Medicare patients (which is covered through the GLP-1 Bridge), and the Lilly Cares Foundation patient assistance program as a fallback. Using the Medical Bill Analyzer can also help identify whether a denied claim was coded incorrectly with an obesity diagnosis code instead of the required type 2 diabetes code.

Patient Assistance Programs

Eli Lilly operates two cost-reduction programs for Mounjaro in 2026: the Mounjaro Savings Card for commercially insured patients with a type 2 diabetes prescription, and the Lilly Cares Foundation patient assistance program for uninsured income-qualified patients. Both programs require a type 2 diabetes diagnosis; neither program is available for weight-loss-only use of Mounjaro. Patients without a diabetes diagnosis who want manufacturer assistance should ask their prescriber about Zepbound, which may qualify for separate Lilly cost programs with an obesity indication. Without insurance, a patient paying full retail faces roughly $13,000 per year in drug cost alone before any manufacturer coupon or program applies:

Medicare Part D

Medicare Part D covers Mounjaro when prescribed for type 2 diabetes mellitus. Coverage for weight loss alone is prohibited under the 2003 Medicare Modernization Act, which explicitly excluded anti-obesity drugs from Part D benefits. Most Part D formularies place Mounjaro on a specialty formulary tier (Tier 4 or 5), requiring prior authorization that includes documentation of a type 2 diabetes diagnosis (ICD-10 E11.x), recent HbA1c lab results, and often a documented trial of metformin or another first-line agent. The Inflation Reduction Act of 2022 created the $2,100 annual out-of-pocket cap for all Part D drugs in 2026. Mounjaro does not have its own specific monthly cap; patients pay until the $2,100 annual cap is reached, after which covered drugs cost $0 for the rest of the year.

Medicare patients specifically seeking GLP-1 coverage for weight loss in 2026 should know that the new GLP-1 Bridge program (effective July 1, 2026) does not include Mounjaro. The Bridge covers Wegovy (all formulations), Zepbound (KwikPen), and Foundayo for weight loss at a $50 monthly copay. The $50 copay under the Bridge does not count toward the $2,100 annual Part D out-of-pocket cap, and Low Income Subsidy (Extra Help) cost-sharing reductions do not apply to it either. Medicare beneficiaries wanting tirzepatide-based coverage for weight loss through the Bridge must have Zepbound specifically prescribed, not Mounjaro. Contact your Part D plan directly or call 1-800-MEDICARE to verify formulary placement and prior authorization requirements for Zepbound under the Bridge.

Medicare beneficiaries who cannot use the savings card (blocked by federal anti-kickback statute) have two primary options for reducing Mounjaro cost for diabetes: the Low Income Subsidy (Extra Help) program administered by Social Security, and, for those who lack any Part D coverage, the Lilly Cares Foundation PAP. Eligibility for Medicare Extra Help is based on income and resources; in 2026, single beneficiaries with annual income below approximately $22,590 and limited assets may qualify. Check Medicare eligibility to confirm qualification, then apply through the Social Security Administration at ssa.gov/medicare/part-d-extra-help.

Common Mounjaro Weight Loss Coverage Billing Errors

Most costly Mounjaro billing errors in 2026 involve the indication on the claim rather than the hospital charge. Watch for these scenarios when reviewing an explanation of benefits or pharmacy claim:

• Claim denied because the diagnosis code is obesity (E66.x) instead of type 2 diabetes (E11.x): Medicare and most commercial plans deny Mounjaro when the primary diagnosis code is obesity. If your prescriber documented only an obesity code and Mounjaro is being prescribed for diabetes management, ask the prescriber to correct the diagnosis coding on the prior authorization request and resubmit.
• Mounjaro billed in place of Zepbound (or vice versa): Mounjaro (NDA 215866) and Zepbound (NDA 217806) are different products with different NDC codes and different FDA labels. A pharmacy dispensing system that crosswalks the wrong NDC will generate a formulary mismatch, a prior auth failure, or a price discrepancy. Always verify the brand name on the prescription matches what is dispensed. If you are a Medicare patient seeking the GLP-1 Bridge, Zepbound must appear on the prescription, not Mounjaro.
• Savings card rejected at pharmacy because Medicare is the primary payer: The Mounjaro Savings Card is not combinable with Medicare, Medicaid, TRICARE, VA, or any federal program. If a commercially insured patient has Medicare as a secondary payer, the savings card is still blocked. The anti-kickback statute (42 U.S.C. Section 1320a-7b) is the controlling law. Attempting to use the card with government insurance results in a processing rejection.
• Prior authorization denied due to missing clinical documentation: Most formularies require evidence of a type 2 diabetes diagnosis, recent HbA1c results, and often a documented trial of metformin before approving Mounjaro. If the PA is denied for clinical insufficiency, ask your prescriber to attach the relevant chart notes (HbA1c lab results, metformin trial documentation, and cardiovascular risk factors if applicable) to the resubmission. Step-therapy requirements are the most common denial trigger for commercially insured patients.
• Patient billed at full list price despite having an active savings card: Pharmacies occasionally fail to process the Mounjaro Savings Card on the first fill, charging the full $1,079.77. If you have commercial insurance and a type 2 diabetes diagnosis and were charged more than $25, ask the pharmacist to reprocess the claim with the savings card enrolled via mounjaro.lilly.com/savings-resources. Keep the savings card enrollment confirmation as documentation.

Frequently Asked Questions